EMA, MIT Form Research Project for Regulatory Science - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

EMA, MIT Form Research Project for Regulatory Science


ePT--the Electronic Newsletter of Pharmaceutical Technology

The European Medicines Agency (EMA) and the Massachusetts Institute of Technology’s (MIT's) Center for Biomedical Innovation (CBI) and Center for International Studies (CIS) are launching a collaborative research project with a focus on enhancing regulatory science in pharmaceuticals, according to an EMA press release.  

The project, which is scheduled to be completed by December 2011, will be conducted within the framework of CBI’s New Drug Development Paradigms (NEWDIGS) research program in cooperation with EMA and CIS. The project will address the following specific questions:

• How to adapt current regulatory requirements to support the efficient development of safe and effective drugs

• How to incorporate patient valuation of health outcomes and benefit–risk preferences into regulatory decision-making

• How to implement “staggered and progressive” approaches to drug approval

• How to improve the fulfillment of postmarketing regulatory requirements. 

The data and recommendations from this project are expected to link to the implementation of EMA’s Roadmap to 2015, a plan for the agency's strategic development for the next five years, and to the NEWDIGS research program. The project will explore the feasibility of, priorities for, and practical considerations of implementing demonstration projects on some of the issues addressed during the course of the research.

ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
29%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
13%
Regulatory compliance
31%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Report: Pfizer Makes $101 Billion Offer to AstraZeneca
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Source: ePT--the Electronic Newsletter of Pharmaceutical Technology,
Click here